A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way

Eur J Pharmacol. 2024 Feb 24:176451. doi: 10.1016/j.ejphar.2024.176451. Online ahead of print.ABSTRACTPancreatic cancer, particularly pancreatic ductal adenocarcinoma, remains a devastating disease with a dismal prognosis and limited survival rates. Despite various drug treatments and regimens showing promise in managing the disease, the clinical outcomes have not significantly improved. Immunotherapy however, has become a forefront area in pancreatic cancer treatment. This approach comprises a range of agents, including small molecule drugs, antibodies, combination therapies, and vaccines. In the last 5-8 years, there has been an upsurge of research into the use of monoclonal antibodies to block receptors on cancer or immune cells, revolutionising cancer treatment and management. Several targets have been identified and studied, with the most encouraging noted in relation to checkpoint markers, namely, antibodies targeting anti-programmed cell death 1 (PD-1) and its receptor PD-L1. Herein, we present the clinical developments in immunotherapy in the last 5 years especially those which have been tested in humans against pancreatic cancer.PMID:38408598 | DOI:10.1016/j.ejphar.2024.176451
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research